Recommendations for introducing novel therapies into earlier lines of therapy for patients with transplant-eligible and transplant-ineligible multiple myeloma.
EP. 1: Transplant Eligibility Criteria in Multiple Myeloma
Impressions of the case of a 51-year-old man with newly diagnosed multiple myeloma and considerations that impact candidacy for an autologous stem cell transplant.
EP. 2: Frontline Treatment for Transplant-Eligible Multiple Myeloma
An overview of doublet and triplet regimens used as first-line therapy for patients with newly diagnosed multiple myeloma who are eligible for transplant.
EP. 3: Quadruplet Regimens for Transplant-Eligible Multiple Myeloma
Implications of updated data from the GRIFFIN trial, in terms of using quadruplet therapy to manage patients with newly diagnosed multiple myeloma who are eligible for transplant.
EP. 4: Transplant-Eligible Multiple Myeloma: When to Move to Transplant
Recommendations regarding the appropriate number of cycles of induction therapy before sending a patient with multiple myeloma for stem cell transplantation.
EP. 5: Consolidation Therapy Post-Transplant in Multiple Myeloma
The current rationale for managing a patient with newly diagnosed multiple myeloma with consolidation therapy post-transplant.
EP. 6: Frontline Therapy for Transplant-Ineligible Multiple Myeloma
An overview of treatment regimens available for patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation.
EP. 7: Tailored Treatment Decisions for Transplant-Ineligible Multiple Myeloma
Various considerations affect choice of first-line therapy for a patient with newly diagnosed multiple myeloma who is ineligible for transplant.
EP. 8: Transplant-Ineligible Multiple Myeloma: Triplet vs Quadruplet Therapy
Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.
EP. 9: Minimal Residual Disease as a Biomarker in Multiple Myeloma
What needs to be investigated further before adopting MRD assessments for multiple myeloma into routine clinical practice.
EP. 10: Preferences for Managing Relapsed Multiple Myeloma
Treatment options available for an elderly man with multiple myeloma upon first relapse.
EP. 11: Sequencing Novel Therapies Into Multiple Myeloma Treatment Algorithms
Recommendations regarding best approaches to using novel therapies to treat multiple myeloma based on current drug approvals as well as new therapies in the pipeline.
EP. 12: Future Perspectives: Treating Multiple Myeloma With Novel Regimens
An overview of what’s next, in terms of the use of various frontline treatment regimens, that include novel agents to manage patients with newly diagnosed multiple myeloma.
EP. 13: Recap: Treatment Options in Transplant-Eligible and -Ineligible Multiple Myeloma
2 Clarke Drive Cranbury, NJ 08512